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C-Reactive Protein (CRP) as a Marker in Peripheral Vascular Disease
A. Abdellaoui and H. Al-Khaffaf*
East Lancashire Hospitals NHS Trust, General/Vascular Surgery, Burnley General Hospital,
Casterton Avenue, Burnley, Lancashire BB10 2PQ, United Kingdom
Objective. To review the role of CRP as a marker for the prediction of development of Peripheral Vascular Disease (PVD)
and as a prognostic indicator.
Methods. Search of the Cochrane Vascular Group Control Trials Register, Medline and Embase for all published studies on
the role of CRP as a marker in peripheral vascular disease was undertaken.13 prospective studies were found.
Results. 12 of the 13 prospective studies showed a strong association between CRP and PVD. Three population studies
involving 16561 people, over a period of 6.5 to 12 years, revealed that high CRP levels approximately tripled the risk of
developing PVD, independently of all other risk factors. Three case-control studies found that hsCRP was much higher
in patients with PVD. Four other studies, which covered 2337 people, demonstrated that CRP levels were associated
inversely with lower ankle brachial pressure index. One study conducted on 384 people failed to show a link between
hsCRP and progression of ABPI. Two further small studies showed that raised pre and post intervention hsCRP were
associated with restenosis after angioplasty.
Conclusions. CRP appears to be a strong predictor and marker of severity of PVD and also may predict the risk of
restenosis after angioplasty.
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High sensitivity C-reactive protein
CRP is a pentameric protein,1 which was discovered
70 years ago.2 Historically, CRP has been used in the
diagnosis and monitoring of active inflammation
and infection. In response to tissue damage or infec-
tion, hepatocytes are stimulated by cytokines, espe-
cially IL6, IL1 and TNFa, to synthesise CRP. CRP
binds to polysacharides of many bacteria in the pres-
ence of calcium. This results in the activation of classic
complement pathway and can promote phagocytosis
and opsonisation.3e5
In mild inflammation and viral infection, CRP incre-
ases to 10e50 mg/l. However, in active inflammation
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50 and 200 mg/l. High concentrations are seen in
severe infections.
Traditional CRP immunoassays are unable to accu-
rately measure CRP concentrations smaller than
5 mg/l. However, high sensitivity CRP techniques,
using monoclonal and polyclonal antibodies (ELISA),
can measure concentrations of high sensitivity CRP as
small as 0.15 mg/l.
There is currently ongoing debate as to the base
line hsCRP measurement in a person, due to the daily
variability in influencing factors, such as obesity6 in-
fections, HRT and smoking.7 HsCRP should only be
performed on patients in a metabolically stable condi-
tion, without any obvious inflammatory or infectious
condition. CDC (Centres for Disease Control and
Prevention) and The American Heart Association rec-
ommend taking two measurements at an interval
of at least 2 weeks separation, especially when the
CRP concentration is greater than 10 mg/l. They
have identified 3 risk groups of people: (1) a lowrved.
19CRP as a Marker in Peripheral Vascular Diseaserisk group with CRP concentrations less than 1 mg/l;
(2) a moderate risk group with CRP between 1 and
3 mg/l; (3) a high risk group when CRP is higher
than 3 mg/l.8
More recently, chronic inflammation has been iden-
tified as a component in the development and pro-
gression of atherosclerosis and CRP has been found
to be a marker of cardiovascular risk.9e12 Recent stud-
ies showed that high concentrations within a normal
range (<5 mg/l) can predict future cardiovascular
events.13e17
CRP specificity and sensitivity in peripheral
vascular disease
Traditional CRP tests designed to monitor acute and
chronic inflammation had poor sensitivity in the
lower ranges and higher sensitivity CRP (hsCRP) tests
have been developed. This has resulted in the recom-
mendation of cut-off levels of hsCRP <1, 1 to 3 and
>3 mg/l, equating to low, moderate and high risk
for future cardiovascular events. If the CRP levels
are>10 mg/l, it is recommended that repeat measure-
ments are taken after two weeks, to rule out any co-
existing infection and accurately measure the hsCRP
base line.
There is continuing debate about the specificity of
CRP in predicting Peripheral Vascular Disease, as
atherosclerosis is a generalised disease and patients
with PVD might have sub clinical ischaemic heart
disease. The Physicians’ Health Study showed a strong
link between hsCRP and PVD, independently of all
other risk factors, including heart disease.17
Materials and Methods
We searched the Cochrane Vascular Group Control
Trials Register (2004), Medline (Jan 66eOct 05) and
Embase for all published prospective cohort studies
and prospective case control studies on the role of
CRP as a marker in PVD, using the keywords: Peri-
pheral Arterial Disease; Peripheral Vascular Disease;
PAD; PVD; CRP; C-reactive protein.
The studies had to include patients with PAD that
had been diagnosed using ABPI or angiography and
had undergone measurement of hsCRP. All cases
were considered and there was no restriction on spe-
cific population groups or settings. Outcome mea-
sures were the levels of hsCRP correlated to the
development or severity of PVD.
Abstracts returned from the search were manually
checked for relevance, according to the above criteria.
Review articles identified in this process weresurveyed for additional and earlier citations. From
the abstracts, 31 relevant studies were found, for
which full articles were obtained. 15 articles were ex-
cluded, since their main subject was not PVD. From
the 16 remaining studies, 3 duplicate publications
were identified and excluded.Data were manually ex-
tracted from the 13 included studies, including the
number of patients, number of males, number of
females, type of study, length of study, end point,
results and recommendations.
Results
CRP and the risk of developing peripheral vascular disease
We found 3 studies that investigated the risk of devel-
oping PVD in a healthy population. All studies found
a strong link between hsCRP and future development
of PVD. These studies assessed 16561 individuals over
periods ranging between 6.5 and 12 years. The risk of
developing Peripheral Vascular Disease ranged be-
tween an odds ratio (OR) of 1.9 and a relative risk
(RR) of 2.8.
Ridker et al. compared 11 inflammatory markers in
14916 initially healthy US male physicians over a 9
year period (Table 1). 140 of the participants devel-
oped PVD. This group was matched to a control
group following age and risk factors. HsCRP was
the strongest non lipid predictor of PVD (RR for the
highest vs lowest quartile, 2.8; 95% CI: 1.3 to 5.9).
The median CRP levels were significantly higher at
base line among the participants who developed
PVD (1.34 vs 0.99 mg/l; P¼ 0.04). This study showed
nearly a three fold increased risk of developing PVD
in asymptomatic subjects.17,18
In the Edinburgh Artery Study a population of 1592
people were followed over a 12 year period. HsCRP
was measured at base line, 5 years and 12 years,
and were correlated to the patients’ symptoms and
ABPI. This study identified HsCRP as a useful predic-
tor of PVD and its progression. The mean hsCRP was
2.7 mg/l in symptomatic patients compared to 1.7 in
the control group (p¼ 0.02).19
Van der Meer et al. measured hsCRP levels in a
random sample of 773 participants (age 55). Sub-
clinical atherosclerosis was measured at various sites
in the arterial tree on 2 different occasions, with
a mean time between assessment of 6.5 years. In iliac
and lower extremity atherosclerosis, risk of PVD in-
creased across quartiles of CRP with iliac OR, 2.2;
95% CI: 1.3 to 3.8 and lower extremity OR, 1.9; 95%
CI: 0.9 to 4.1. This study concluded that CRP predicts
the progression of PVD.20Eur J Vasc Endovasc Surg Vol 34, July 2007
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2007able 1. Summary of the prospective studies that have investigated the role of CRP in PVD
tudy Country Type of study No. of patients Length of the study
RP and the Risk of Developing PVD
idke et al. (2001)
hysicians health study
USA Prospective
Case Control
14196 9 years
zoulaki et al. (2005)
dinburgh Artery Study
UK Cohort 1592 12 years
an Der Meer et al. (2002) Netherlands Cohort 773 6.5 years
RP in Patients with PVD
loemenkamp et al. (2002) Netherlands Case Control 687 e
u et al. (2005) USA Cross-sectional 1600 e
assar et al. UK Case Control 202 e
RP and ABPI
ozawa et al. (2004) Japan Cross-sectional 946 e
ainas et al. (2005) Netherlands Cohort 387 12 months
cDermott et al. (2003) USA Observational 601 e
usicant et al. (2006) USA Cohort Study 384 1e99 months (mean 3
boyans et al. USA Longitudinal Cohort 403 4.6 2.5 Years
RP and Outcome of Angioplasty
chillinger et al. (2002) Austria Prospective Cohort 172 6 months
chillinger et al. (2003) Austria Prospective Cohort 89 6 months
I: Confidence Interval, OR: Odds Ratio, RR: Relative Risk, PVD: Peripheral Vascular Disease.
21CRP as a Marker in Peripheral Vascular DiseaseThe different designs and reporting of these studies
precluded calculation of a pooled risk estimate in
a formal meta-analysis.
CRP in patients with peripheral vascular disease
We found 3 studies that evaluated hsCRP levels in pa-
tients already affected by Peripheral Vascular Disease.
All studies found that HsCRP was much higher in
patients with PVD compared to a control group.
Bluemenkamp et al. compared 212 young women
(age 48 8.1 years) with PVD to a control group of
475 healthy women. The study concluded that ele-
vated hsCRP levels were associated with an increased
likelihood of PVD (OR¼ 3.9; 95% CI: 1.8 to 8.5 for
women in the third quartile; OR¼ 3.1; 95% CI: 1.4 to
6.8 for women in the fourth quartile).21 Cassar et al.
showed that HsCRP levels were significantly higher
in patients with PVD, with an average CRP of
3.4 mg/l range 0.15e24 (p< 0.001).22 In a third study,
Vu et al. concluded that patients with metabolic syn-
drome and hsCRP higher than 3 mg/l have an in-
creased risk of PVD. This risk was much greater in
diabetic patients, OR of 4.79 (95% CI 1.42e16.11,
p¼ 0.01) compared to OR 8.57 (95% CI 2.16e34.02,
p¼ 0.001) respectively.23
CRP and ABPI
We found 5 Studies that looked into the relationship
of hsCRP and PVD; four of them concluded that
ABPI was significantly inversely associated with
hsCRP.
McDermott et al. investigated the relationship be-
tween different inflammatory markers and ABPI in
patients with and without PVD, 370 men and women
with PVD (ABPI< 0.90) and 231 without PVD. ABPI
was significantly inversely associated with hsCRP.24
This study also concluded that higher CRP levels
were associated with a poorer 6 minute walk
performance.25
Vainas et al. studied 387 PVD patients, at baseline
and 12 months, looking for progression of the disease
and future events. They concluded that hsCRP was
related to the severity of PVD (p< 0.01) and develop-
ment of future cardiovascular events including death
(p¼ 0.04).26
In the Tsurugaya Project Hozawa et al. looked at the
relationship between hsCRP and ABPI in 946 elderly
Japanese (>70 year old). They found that higher
CRP levels were independently associated with
a lower ABPI, OR 5.79(95% CI: 2.99e11.2).27 Aboyans
et al. showed a borderline association between hsCRPand the progression of ABPI for large vessel disease
(P¼ 0.05).28
In contrast, another study found no significant
association between hsCRP and progression of ABPI
in a study conducted on 384 subjects, results attri-
buted to small sample size and limited follow up.29
CRP and outcome of angioplasty
Schillinger et al. looked at the risk of restenosis follow-
ing above and below knee angioplasty in two differ-
ent prospective studies. They concluded that raised
pre and post-angioplasty hsCRP levels were indepen-
dently associated with restenosis at 6 months.30,31
The first prospective cohort study was conducted
on 89 patients with PVD, who underwent a successful
below knee angioplasty, and restenosis occurred in 36
patients.30 Patients with pre-intervention CRP levels
of 2.3e9.2 mg/l had a 3.7 fold increased risk of re-
stenosis (OR¼ 3.7; 95% CI: 1.0 to 13.5; P¼ 0.05). If
CRP> 9.2 mg/l there is a 4.7 fold increased risk of
restenosis (OR¼ 4.7; 95% CI: 1.2 to 18.5; P¼ 0.03).
Post intervention CRP greater than 24.2 mg/l was as-
sociated with a 10.7 fold adjusted risk of restenosis
(OR¼ 10.7; 95% CI: 2.4 to 47.6; P¼ 0.02). In the second
study, 172 patients underwent a successful above knee
angioplasty.31 Restenosis was found in 56 patients
(33%) within 6 months. CRP values at baseline (OR,
2.3; 95% CI:1.1, 4.2) and 48 hours after angioplasty
(OR, 2.3; 95% CI:1.6, 3.1) were independently associ-
ated with restenosis at 6 months.
Conclusion
Cholesterol concentrations remain used widely to de-
termine the risk of developing ischemic heart disease,
although it is well known that approximately 50% of
patients with myocardial infarction have normal cho-
lesterol levels. HsCRP has shown promising results in
predicting the developments and severity of coronary
heart disease, and more recently, Peripheral Vascular
Disease. PVD should be investigated in a similar man-
ner to coronary heart disease, with patients divided
into low (CRP< 1 mg/l), moderate (CRP between
1 and 3 mg/l) and high risk (CRP> 3 mg/l) groups.
There are likely to be several limitations to the
studies that we identified. For instance, positive case
control studies are more likely to be reported than
negative ones. In some studies blood samples were
taken only once, therefore the individual variation
could not have been taken into account. However,
we found sufficient evidence to conclude that CRP
can be used to predict the development of PVD andEur J Vasc Endovasc Surg Vol 34, July 2007
22 A. Abdellaoui and H. Al-Khaffafassess its severity. It also shows promise in the predic-
tion of the outcome of angioplasty, but larger studies
are needed to confirm this.
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